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Key Clinical Message
Tardive dystonia is a risk factor in medical antipsychotic treatment. It often
begins with repetitive involuntary jaw and tongue movements resulting in
impaired chewing and detrimental effect on the dentition. The orofacial dys-
function may go unrecognized in a neurological setting. The diagnosis may be
difficult so we suggest interdisciplinary collaboration.
Keywords
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Background
Dystonia is characterized by abnormal involuntary move-
ments of muscles (WHO ICD-10 G24). The disease can be
divided into idiopathic, genetic, and acquired, that is,
resulting from environmental or other damage to the brain
or from exposure to dopamine receptor blocking agents
such as antipsychotics, antitussive drugs, and antiemetics.
However, the pathophysiology of TD is unclear.
The acute drug-induced dystonia develops days or
weeks after start of the antipsychotic treatment [1]. Char-
acteristic signs are acute affection of the ocular muscles
with prolonged deviation of the eyes in an upward direc-
tion (oculogyric crises), stiffness in the neck and shoulder,
and tongue protrusion. It often ceases if the medications
are stopped quickly. Drug-induced dystonia with a
delayed onset also referred to as tardive dyskinesia (TD),
usually begins in the throat, face, and masticatory muscles
as a form of oromandibular dystonia (OMD) with repeti-
tive, complex chewing motions, but other tardive syn-
dromes such as drug-induced chorea may also appear. It
may also spread to the whole body even if the medication
is stopped [2].
The forceful contractions and persistent repetitive dys-
tonic movements are associated with difficult opening or
closing of the mouth and affect chewing, swallowing, and
speech [3, 4]. It may also cause bruxism during wakefulness
with excessive teeth grinding and jaw clenching that result
in tooth wear and damage of dental restorations. Making
the diagnosis is sometimes not so easy. Patients may be
misdiagnosed as having similar and perhaps related
disorders such as Parkinson’s disease, essential tremor,
Tourette’s syndrome, temporomandibular disorders, noc-
turnal bruxism, and even primary denture problems. So
there are many differential diagnoses. Consequently, the
diagnostic delay is often significant. Multidisciplinary
collaboration with exchange of knowledge is therefore
advisable. Efficient diagnosis may also require electromyo-
graphic and dental examinations as well as paraclinical tests
in terms of scannings and blood tests.
In patients receiving antipsychotic medication, the inci-
dence over a 4-year period is approximately 20% with
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highest incidence in middle-aged and elderly patients,
particularly women. To prevent TD, the lowest possible
dose should be used, when antipsychotics are needed and
second-generation antipsychotics should probably be pre-
ferred [5]. Intramuscular injections with botulinum toxin
(BTX) and deep brain stimulation may be helpful for
decreasing TD [6].
Patients and Methods
The characteristics and treatment are described in two
elderly women, Patients A and B, with persistent drug-
induced TD based on history, clinical, video and elec-
tromyographic recordings, blood tests, and imaging at the
Department of Neurology and Clinical Neurophysiology,
Department of Clinical Biochemistry, the Department of
Radiology and Imaging in the Bispebjerg University
Hospital, and the Department of Odontology, University
of Copenhagen. Written informed consent was obtained
to publish their data extracted from the electronic records
in the departments in an anonymized form.
As shown in Figure 1A and B, their medical history
included a variety of drugs prior to referral, including
antipsychotic and antidepressant treatment, which may
induce TD. The data on their previous medication are
partly obtained retrospectively. The content in the figures
is based on the available information on their drug con-
sumption during the period of respectively 6 (Patient A)
and more than 60 years (Patient B).
Patient A
Referral
A woman born in 1945 referred for constant munching and
biting. Besides the long-term use of antipsychotic medicine,
her medical history also included genetically predisposition
and signs of Parkinson’s disease (Fig. 1A), which could be
relevant for diagnosis of her movement disorder.
Status at the time of referral to the hospital
(2016)
Socially handicapped and extremely bothered by reduced
eye blinking, oromandibular, mainly biting movements,
oligomimia, intermittent right-sided resting tremor
enhanced by mirror movements, and slight rigidity at the
right side. MR scanning showed sequelae from left-sided
thalamus infarction, which could explain some of her
symptoms. Current medication was antiepileptics (Clon-
azepam and Gabapentin), antidepressants and antianxiety
(Fluoxetine and Diazepam), antiplatelet drugs (Clopido-
grel), hypnotics (Zolpidem), and analgesics (Paracetamol
and Codeine).
Clinical follow-up, scannings, further
diagnostics, and treatment
Initially, there was good effect from the current medica-
tion on the orofacial dyskinesia but increasing parkinson-
ism and problems with the gait. Findings in DAT-SPECT
scannings in 2015 and 2016 were normal and symmetrical
and could not support the diagnosis of Parkinson’s dis-
ease. Higher doses of Diazepam decreased the parkinson-
ism. Hence, the clinical status showed only slurred speech
and bucco-linguo-masticatory (BLM) syndrome with jaw
and lip protrusion and vermicular tongue movements.
Increased doses of Clonazepam reduced the BLM syn-
drome slightly. As her jaw function was impaired, she was
referred for oromandibular and dental evaluation.
Oromandibular evaluation including
electromyography (2017)
Impaired orofacial function with a high impact on daily
life (Table 1) with constant bruxing and munching move-
ments at a frequency of ½–1 Hz, often chewing of cheeks
and tongue, and local fatigue and tenderness. The subjec-
tive visual analog scale (VAS) for the impact of OMD on
daily life was 9 (0–10), and the Fahn–Marsden Dystonia
Rating Scale (F-M DRS for mouth) 8 (0–8). The involun-
tary movements were reduced when speaking or chewing,
and there were no reports of sleep bruxism. The chewing
was slow and difficult partly because of hyposalivation.
The salivary low secretion rate was probably related to
the drug intake. Quantitative electromyographic (EMG)
recordings showed very high level of resting activity in
masticatory muscles and revealed turns per second higher
than 100 in anterior temporal and lateral pterygoid mus-
cles (Table 1) corresponding to her ongoing jaw move-
ments. The range of jaw opening mobility was normal.
The patient had full and functional complement of teeth,
even if there was heavy tooth wear and damages in the
restorations related to the dystonia. It was concluded that
the functional problems were caused by the dystonic
activity and not related to the dental state.
Additional treatment and diagnosis
As a consequence of the oromandibular findings, intra-
muscular injections with botulinum toxin were planned
to diminish the dystonic bruxing and munching and its
detrimental effects. The patient was treated with repeated
injections of 25 units IncobotulinumtoxinA (BTX) in the
temporalis and lateral pterygoid muscles on each side per-
formed with EMG guidance. Recently, she also com-
plained of severe pain and stiffness in the neck, shoulders,
and arms, which her general practitioner considered to be
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Figure 1. (A) Medical history for Patient A prior to the referral to the University Hospital. (B) Medical history for Patient B prior to the referral to
the University Hospital.
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polymyalgia rheumatica. This was later rejected by blood
tests and might also be related to left-sided thalamic
infarct.
Current status 2017/2018
The combined treatment with medication and injections
has a reducing, moderate effect on the involuntary move-
ments and the jaw fatigue and tenderness. The OMD
impact on daily life was reduced from 9 to 7 1–2 months
after injections when the BTX treatment is most effective
(Fig. 2). In addition, she also wears a hard acrylic occlusal
splint to prevent further dental attrition. However, lately
her tongue has become clinically hyperactive. Corre-
spondingly, EMG reveals a very high level of resting activ-
ity in the genioglossus muscles and turns per second
higher than 100. This can be treated with BTX injections
but are often associated with side effects.
Patient B
Referral
A woman born in 1931 referred for repeated tongue protru-
sion. Besides the long-term use of antidepressant and
antipsychotic medicine, her medical history included a
minor stroke and three suicide attempts with drugs. In
1997, she developed dystonic movements in her thoracic di-
aphragm and soon after also in the oromandibular region.
Status at the time of referral to the hospital
(2009)
Extremely bothered by the involuntary repetitive move-
ments of the tongue in and out of the mouth and
drooling. Current medication to reduce the TD was Leve-
tiracetam, Tetrabenazine, and Orphenadrine, which did
not reduce the TD sufficiently. Her other medication
included Venlafaxine, Alprazolam, Rivastigmine, Asas-
antin for moderate dementia and her psychiatric and
mood disorders, and Atropine for drooling. In general,
the effect of the current pharmacological treatment was
not sufficient.
Table 1. Patient characteristics.
Patient
Oromandibular dystonia Orofacial function
Dominant
dystonia type
Impact
on daily
life
(VAS 0–10)1
F-M
dystonia
rating
scale
(OMD: 0–8)2
Needle
electromyography
(>100 turns/sec)3
Orofacial
dysfunction
screening
(0–12)4
Jaw
Disability
Checklist
(RDC/TMD 0–12)5
Subjective
mastication
index (0–4)6
Chewing
time
(apple
95% CI:
10–47 sec)
A Munching
and biting
9 8 Ant. temporalis,
Lat. pterygoid
6 3 1 64
B Tongue
protrusion
10 8 Genioglossus 7 4 2 84
1visual analog scale.
2Fahn–Marsden Dystonia Rating Scale.
3Werdelin et al. [12].
4Nordic Orofacial Screening – Test [13].
5Research Diagnostic Criteria for Temporomandibular Disorders [14].
6Chewing ability after Yoshida et al. [15].
Figure 2. The effect of BTX injections on daily life in two patients
with drug-induced tardive oromandibular dystonia as measured by
subjective visual analog scales. Patient A with dystonic biting and
bruxing movements was treated with 25 units IncobotulinumtoxinA in
the anterior temporal and lateral pterygoid muscles on both sides.
Patient B with dystonic jaw opening and repeated tongue protrusion
was treated with 15 units IncobotulinumtoxinA in the genioglossus
muscles on both sides. All injections were guided by
electromyography.
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Oromandibular evaluation including
electromyography (2010)
Impaired orofacial function with a high impact on daily
life (Table 1) with jaw opening and repeated tongue pro-
trusion every 5 sec, and marked drooling. The subjective
visual analog scale (VAS) for the impact of OMD was 10
(0–10) and the Fahn–Marsden Dystonia Rating Scale (for
mouth) 8 (0–8). The salivary secretion rate was below
average so the sialorrhea was secondary, that is, due to
insufficient or infrequent swallowing. Speech was weak,
but understandable. Chewing was slow, and tough food
was avoided. EMG showed a very high level of resting
activity and turns per second higher than 100 in the
genioglossus muscles (Table 1) corresponding to the
involuntary protrusive tongue movements. There was
antagonistic activity in the jaw opening muscles during
biting. The range of jaw opening mobility was normal.
The patient had a well-fitting partial denture fixed with
braces in the upper jaw and almost full complement of
teeth in the lower jaw. Thus, the dental state did not
cause the deviant activity although some of the chewing
problems could be associated with the partial denture in
the maxilla. This type of rehabilitation generally improves
the chewing ability, but is not able to fully restore the
masticatory function.
Additional treatment and further diagnostics
As a consequence of the EMG findings, the patient was
treated several times with 15–20 units Incobotulinum-
toxinA in the genioglossus muscles in both sides to inhi-
bit the tongue protrusion. A submandibular approach
and EMG guidance were used with good effect [7]. Two
months after BTX treatment, the VAS for OMD was
reduced from 10 to 5 (Fig. 2) and the FMDRS for the
mouth from 8 to 3. Eventually, the tongue protrusion
decreased (to VAS 1 and FMDRS 0), the drooling was
reduced, and she stopped the BTX treatment. After a cou-
ple of years, parkinsonism emerged. In 2013, Parkinson’s
disease was diagnosed in addition to the TD on the basis
of an abnormal DAT-SPECT with asymmetrically reduced
FP-CIT uptake in striatum.
Current status 2017/2018
She is now treated for Parkinson’s disease with some
reemerging resting tremor of upper extremities and dysto-
nia. She is mobilized with a walker-rollator. In addition
she is largely anarthric and communicates with gestures.
The present medication is Parkinson’s medicine (Car-
bidopa/Levodopa, Benserazide Hydrochloride/Levodopa),
antiepileptics (Levetiracetam), anticholinergic (Orphen-
adrine), antihyperkinetic (Tetrabenazine), antidepressant
(Venlafaxine), antidementia (Rivastigmine), hypnotics
(Zolpidem). With this medication, the patient indicates
further relief of the symptoms.
Discussion and Conclusion
The cases illustrate the problems of treating patients with
psychiatric or mood disorders in an effective way while
avoiding side effects. In general, the most frequent drugs
causing TD are neuroleptics, such as Benzamides, Thi-
ethylperazine, and calcium-channel blockers. Both
patients have been treated with antipsychotics over a long
period of time prior to the emergence of dystonia. Other
drugs had also been administered, and other complaints
and conditions made the diagnosis complicated. A thor-
ough medical history and a multidisciplinary approach
with clinical and paraclinical evaluations such as elec-
tromyography, scannings, and blood tests are important
to make the diagnosis of TD and to treat it as well as to
identify possible differential diagnoses and additional con-
ditions.
Treatment of TD is generally difficult due to limited
data and incomplete understanding of the mechanism,
and it necessitates a stepwise approach [9]. It is also
important to evaluate the TD treatment on an individual
basis with careful consideration of the severity of symp-
toms as in the present cases. Optimization of antipsy-
chotic therapy should be considered before initiation of
medical treatment of the TD [10]. There are no disease-
modifying treatments, but data from recent studies also
indicate possible improvements in TD after switching
from first- to second-generation antipsychotics. However,
there is some evidence of symptomatic treatment with
Clonazepam, Ginkgo biloba, Amantadine, and Tetra-
benazine (American Academy of Neurology, Guidelines
2013), as well as injections with botulinum toxin [10, 11].
If intractable or unresponsive to the array of pharmaceu-
tical interventions, more invasive treatments such as deep
brain stimulation may be considered for TD, but the
extent of the treatment must always be balanced accord-
ing to the degree and impact of the symptoms on daily
life and orofacial function.
The present reports describe two cases with characteris-
tic features of TD diagnosed and treated by a multidisci-
plinary team of movement disorder specialists,
neurophysiologists, and odontological experts in temporo-
mandibular disorders and orofacial pain [8]. However,
the cases were not simple. They illustrate diagnostic prob-
lems and demonstrate that TD patients may also suffer
from disorders with similar symptoms. Therefore, the
interdisciplinary cooperation was essential. In both cases,
the dystonic activity was reduced by a combination of
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pharmacologic treatment and BTX injections in the
muscles.
In Patient A with dystonic bruxing and munching
movements, the condition was more drug-resistant than
in Patient B with dystonic jaw opening and protrusive
tongue movements. However, in both cases TD was sig-
nificantly alleviated but not cured with correction and
changes in the drug intake and/or BTX injections in
the dystonic muscles. Patient A also had a bite splint
to prevent or minimize further attrition and dental
trauma. Later, her TD spread to tongue muscles, which
will be BTX-treated as well. In Patient B, the prosthetic
reconstruction even well-fitted might have contributed
to the impaired chewing function. She stopped the
BTX treatment as the tongue protrusion decreased, but
later she developed Parkinson’s disease and is treated
accordingly.
In conclusion, the two cases with TD show the
importance of detailed medical history, specialist exami-
nations, and interdisciplinary collaboration to ensure a
correct diagnosis. They also illustrate the significance of
following the patient’s clinical presentation and symp-
toms closely over time to tailor the treatment individu-
ally as TD may change and can prove hard to treat.
Lastly, the report demonstrates the orofacial dysfunction
associated with TD, which can easily be overlooked in
a neurological setting. This aspect is essential because
of its effects on the patients’ well-being, social activities,
and nutrition.
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